Interim Phase 4 Data Support TAKHZYRO® (lanadelumab) as an Effective Treatment to Reduce Attacks in Hereditary Angioedema PatientsFebruary 28, 2022Interim Real-World Data from Phase 4 EMPOWER Study Show Attack Rate Reduction and Improvement in Treatment Satisfaction and Other Patient-Reported Outcome Scores.
DGAP-Ad-hoc: Takeda Pharmaceutical Company Limited / Key word(s): Forecast Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2021 (IFRS) 03-Feb-2022
DGAP-Ad-hoc: Takeda Pharmaceutical Company Limited / Key word(s): Forecast Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2021 (IFRS) 03-Feb-2022 / 07:00 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation .
Takeda Pharmaceutical Company Limited / Key word(s): ForecastTakeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2021 (IFRS)03-Feb-2022 / 07:00 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP.